Dr. Di Wu is the Director of Laboratory for International Research and Relations at Clinical Pharmacology & Therapeutics (CPT) in Children's Hospital of Philadelphia (CHOP) and a Guest Professor at Central South University & Third Xiangya Hospital. Dr. Wu currently serves as Clinical Investigator, developing innovative designs for informative clinical trials and experiments and integrated approaches for data analysis at Kinetic Modeling and Simulation core of University of Pennsylvania/CHOP Clinical and Translation Science Award supported by NIH.
Dr. Wu published over 50 peer-reviewed original papers, book chapters and conference abstracts, on clinical and preclinical pharmacology related areas, such as pharmacometrics, drug metabolism, pharmacokinetics/ pharmacodynamics, systems biology, pharmacognosy, and novel bioanalytial approaches. She serves as a reviewer for seven internationally circulated journals and an editorial board member for two journals.
Dr. Wu received her B.S. in Pharmacy in 1992 and M.S. in Biopharmaceutics & Pharmaceutical Analysis in 1995 from China Pharmaceutical University, and Ph.D. in Pharmacognosy in Michigan State University in 2001. Prior to join CHOP, Dr. Wu led project teams at OSU to investigate potentials of a series of compounds for treating chronic lymphocytic leukemia, osteoporosis, cancer cachexia, leishmaniasis and African trypanosomiasis using pharmacometrics and preclinical & clinical pharmacology approaches. She contributed prominently and extensively to investigational new drug (IND) application for selective androgen receptor modulators treating cancer cachexia. Dr. Wu led several bioequivalence studies at CPU when working as Senior Lecturer and Research Associate at CPU. Dr. Wu has extensive and thorough experience in identifying bioactive compounds in traditional medicine and investigating mechanisms of action of traditional medicine in different diseases including kava kava, Gingko Biloba , Sheng Mai Yin, etc.
In 2009, Dr. Wu was elected to the Fellow of Clinical Pharmacology by American College of Clinical Pharmacology (ACCP). Since 2009, Dr. Wu has served the committee of Clinical Pharmacology and Translational Research section in AAPS, and the Public Policy Committee of ACCP, and the Program Committee of AAPS Philadelphia Pharmaceutical Forum, Executive Council of Sino-American Pharmaceutical Professionals Association-Greater Philadelphia Chapter. She is the co-founder and co-Chair of Society of Clinical and Biomedical Research. Dr. Wu initiated Systems Biology in drug discovery and development at AAPS, and became the first Chair for Systems Biology Focus Group at AAPS. She is also a member of American Society of Clinical Pharmacology and Therapeutics (ASCPT).
Dr. Wu was awarded the Second Place for research poster presentation for the excellence of clinical and pharmacometric research in oncology at the 7 th Comprehensive Cancer Center Scientific Meeting in 2005. She was given an Excellent Manuscript Award in the Conference on Development Strategy of Industrial and Healthcare Applications for Chinese Medicine in 2010, and SAPA-GP Outstanding Service Award in 2011. Dr. Wu has been invited to lecture at UPenn KMAS core, Center for Pediatric Clinical Effectiveness at CHOP, Temple University, Hospital 301, Central South University & Third Xiangya Hospital, Tsinghua University and other universities and hospitals.Dr. Wu's research interests lie in conducting clinical trials/research among multi-centers between China and United States, and applying pharmacologic and modeling & simulation approaches to obtain best clinical practice and pharmacotherapy in pediatric and adult population for marketed /exploratory compounds/traditional medicines against a variety of diseases. She utilizes population PK/PD, disease progression modeling, systems biology, and other methods to investigate mechanism of action of drugs, identify and validate disease biomarkers, and human developmental changes and its effects on drug disposition. Dr. Wu is also focusing on interpreting PK/PD and mechanisms of action of traditional medicines. She provides consultation on pharmacy practice in Chinese hospitals. In addition, Dr. Wu is conducting research and consulting on intellectual property, market analysis, and development strategy for pharmaceutical companies.
Milestone achievements for international collaboration
Publications from international collaboration
Hu Z, Zhao Y, Wu D , Cheng Z. Endogenous cortisol 6 beta-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans. Clinica Chimica Acta , 2009 , 408(1-2): 92-97
Zhang Q, Wang G, A J, Wu D , Zhu LL, Ma B, Du Y. Application of GC/MS-based metabonomic profiling in studying lipid-regulating effects of Ginkgo Biloba extract on diet-induced hyperlipidemia in rats. Acta Pharmacologica Sinica , 2009 , 30(12) : 1674-1687
Zhang Q, Wang G, A J, Ma B, Du Y, Zhu L, Wu D* . Metabonomic profiling of diet-induced hyperlipidemia in a rat model. Biomarkers , 2010 , 15(3) : 205-216
Ma B, Zhang Q, Wang G, A J, Wu D , Liu Y, Cao B, Liu L , Hu Y, Wang Y, Zheng Y. GC-TOF/MS-based metabolomic profiling of estrogen deficiency-induced obesity in ovariectomized rats. Acta Pharmacologica Sinica , 2011 , 32 : 270–278
Cao J, Wu D , Miao L, Liu J, Barrett JS . Integrated strategy of systems biology and translational medical research. In: Quantitative Pharmacology and Novel Drug Evaluation, People's Military Medical Press.
Barrett JS . Chapter 3(5): Principles and applications of Bayesian methods in clinical trials. In: Drug Clinical Trial, Honghao Zhou & Hong Yuan eds , People's Medical Publishing House , June 2011
Wu D , Cao Jin, Wang X, Barrett JS* . Considerations on pediatric pharmacotherapy and pediatric clinical trials. (accepted by Journal of Clinical Pediatrics )
Wu D , Shen K, Wang X, Cao J*, Barrett JS* . Applications of pediatric clinical trial design in drug development and evaluation. (accepted by Chinese Journal of Pediatrics )
Media Release on international collaboration